Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02856100
Recruitment Status : Active, not recruiting
First Posted : August 4, 2016
Last Update Posted : December 20, 2018
Sponsor:
Collaborator:
Prostate Cancer Foundation
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering from PCa. In this study we will image patients with CRPC undergoing second-line anti-androgen therapy (enzalutamide or abiraterone) using 18F-DCFPyL-PET/CT for detection of metastases and therapeutic monitoring, with correlation to standard-of-care conventional imaging modalities (CIM) (CT, bone scan) and clinical follow-up.

Condition or disease Intervention/treatment
Prostate Cancer Drug: 18F DCFPyL- Radiopharmaceutical

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
Actual Study Start Date : August 3, 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients with CRPC, evidence of metastases, planned treatment Drug: 18F DCFPyL- Radiopharmaceutical



Primary Outcome Measures :
  1. Change in number of metastatic lesions detected on 18F-DCFPyL PET/CT [ Time Frame: up to 2 years ]
    Change in number of metastatic lesions detected from baseline standard of care conventional imaging (CT and Bone Scan) to 18F-DCFPyL PET/CT at 8-12 weeks post- anti-androgen therapy (standard of care)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with CRPC and planned treatment with evidence of metastases on conventional imaging modality (CIM) (CT and/or bone scan)
Criteria

Inclusion Criteria:

  • Willing and able to provide written informed consent
  • Age ≥ 18 years and male
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
  • Patients starting abiraterone (but naïve to enzalutamide) or starting enzalutamide (but naïve to abiraterone)
  • Prior docetaxel-based chemotherapy is permitted but not required
  • Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following:

    • Rising PSA over a minimum 1-week interval
    • Radiographic progression in soft tissue and/or bone
  • Ongoing androgen deprivation with serum testosterone < 50 ng/dL (< 1.7 nM)
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Hemoglobin ≥ 90 g/L independent of transfusion
  • Platelet count ≥ 100,000/μL
  • Serum albumin ≥ 30 g/L
  • Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
  • Serum potassium ≥ 3.5 mmol/L

Exclusion Criteria:

  • Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  • Abnormal liver functions consisting of any of the following:

    • Serum bilirubin ≥ 1.5 x ULN (except for patients with documented Gilbert's disease)
    • AST or ALT ≥ 2.5 x ULN, (for patients with known liver metastasis, AST or ALT ≤ 5 x ULN is allowed)
  • Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg)
  • Active or symptomatic viral hepatitis or chronic liver disease
  • History of pituitary or adrenal dysfunction
  • Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
  • Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 12 months
  • Known brain metastasis
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of orally administered hormonal agents.
  • Acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a NCI CTCAE (version 4.0) grade of ≤ 1; chemotherapy-induced alopecia and grade 2 peripheral neuropathy are allowed
  • Current enrollment in an investigational drug or device study, or participation in such a study within 30 days of first administration of the hormonal agent.
  • Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
  • Not willing to comply with the procedural requirements of this protocol
  • Patients who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration
  • Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02856100


Locations
Layout table for location information
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Foundation
Investigators
Layout table for investigator information
Principal Investigator: Steven Rowe, MD, PhD Johns Hopkins University

Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT02856100     History of Changes
Other Study ID Numbers: J15232
IRB00082289 ( Other Identifier: JHMIRB )
First Posted: August 4, 2016    Key Record Dates
Last Update Posted: December 20, 2018
Last Verified: December 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action